{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:53:20Z","timestamp":1792886000872,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.coi.2015.05.007","type":"journal-article","created":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T10:06:45Z","timestamp":1433758005000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["New approaches to HIV vaccine development"],"prefix":"10.1016","volume":"35","author":[{"given":"Barton F","family":"Haynes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2015.05.007_bib0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2015.05.007_bib0345","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1084\/jem.20090365","article-title":"The first T cell response to transmitted\/founder virus contributes to the control of acute viremia in HIV-1 infection","volume":"206","author":"Goonetilleke","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0350","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nri3478","article-title":"Unravelling the mechanisms of durable control of HIV-1","volume":"13","author":"Walker","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2015.05.007_sbref0355","doi-asserted-by":"crossref","first-page":"1237874","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_sbref0360","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.05.007_bib0365","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0370","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0375","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2","volume":"490","author":"Rolland","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.05.007_bib0380","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2015.05.007_bib0385","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0390","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2015.05.007_bib0395","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"Pollara","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_sbref0400","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.coi.2015.05.007_bib0405","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1128\/JVI.00198-11","article-title":"The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection","volume":"85","author":"Gray","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0410","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1128\/JVI.05363-11","article-title":"Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals","volume":"85","author":"Tomaras","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0415","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature's pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.coi.2015.05.007_bib0420","doi-asserted-by":"crossref","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2015.05.007_bib0425","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cell.2015.03.004","article-title":"Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection","volume":"161","author":"Wu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.coi.2015.05.007_bib0430","doi-asserted-by":"crossref","first-page":"e23532","DOI":"10.1371\/journal.pone.0023532","article-title":"Isolation of a human anti-HIV gp41 membrane proximal region neuralizing antibody by antigen-specific single B cell sorting","volume":"6","author":"Morris","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2015.05.007_bib0435","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus Tupe 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.coi.2015.05.007_bib0440","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.20121977","article-title":"Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies","volume":"210","author":"Yang","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0445","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/JVI.02378-14","article-title":"Polyreactivity and autoreactivity among HIV-1 antibodies","volume":"89","author":"Liu","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0450","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"Haynes","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_bib0455","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.coi.2011.04.003","article-title":"Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies","volume":"23","author":"Verkoczy","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2015.05.007_bib0460","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.4049\/jimmunol.1300770","article-title":"Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10,","volume":"191","author":"Chen","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2015.05.007_sbref0465","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.4049\/jimmunol.1300971","article-title":"Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses","volume":"191","author":"Verkoczy","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2015.05.007_bib0470","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.1301285","article-title":"Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10","volume":"191","author":"Doyle-Cooper","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2015.05.007_bib0475","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"Moldt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2015.05.007_bib0480","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.coi.2015.05.007_sbref0485","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2013.09.061","article-title":"Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys","volume":"155","author":"Barouch","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coi.2015.05.007_sbref0490","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol Therapy"},{"key":"10.1016\/j.coi.2015.05.007_bib0495","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)","volume":"207","author":"Barouch","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2015.05.007_bib0500","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nrmicro3360","article-title":"Novel vaccine vectors for HIV-1","volume":"12","author":"Barouch","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.coi.2015.05.007_bib0505","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm1461","article-title":"Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants","volume":"13","author":"Fischer","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0510","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1128\/JVI.00114-09","article-title":"T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces","volume":"83","author":"Korber","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0515","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00383-15","article-title":"Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus and trivalent mosaic Envelope vaccines formulated as a DNA prime, NYVAC and Envelope protein boost","author":"Hulot","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0520","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"Letourneau","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2015.05.007_bib0525","doi-asserted-by":"crossref","first-page":"e86254","DOI":"10.1371\/journal.pone.0086254","article-title":"Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques","volume":"9","author":"Kulkarni","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2015.05.007_bib0530","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12967-015-0392-5","article-title":"A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques","volume":"13","author":"Mothe","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0535","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.immuni.2013.08.031","article-title":"Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses","volume":"39","author":"Locci","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2015.05.007_bib0540","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.1987.tb04157.x","article-title":"Anticardiolipin antibodies associated with HTLV-III infection","volume":"65","author":"Canoso","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2015.05.007_bib0545","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0090-1229(91)90134-V","article-title":"AIDS virus infection and autoimmunity: a perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease","volume":"58","author":"Morrow","year":"1991","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.coi.2015.05.007_sbref0550","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cell.2014.10.046","article-title":"Accelerating HIV-1 vaccine efficacy trials","volume":"159","author":"Barouch","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.coi.2015.05.007_bib0555","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1126\/science.1254990","article-title":"AIDS\/HIV Host controls of HIV neutralizing antibodies","volume":"344","author":"Haynes","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_bib0560","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"Haynes","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coi.2015.05.007_sbref0565","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"Liao","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.05.007_sbref0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.05.007_sbref0575","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/nm.2985","article-title":"Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape","volume":"18","author":"Moore","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0580","doi-asserted-by":"crossref","first-page":"e1003738","DOI":"10.1371\/journal.ppat.1003738","article-title":"Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes","volume":"9","author":"Wibmer","year":"2013","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.coi.2015.05.007_sbref0585","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2014.06.022","article-title":"Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies","volume":"158","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.coi.2015.05.007_sbref0590","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1126\/science.1245627","article-title":"Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Lyumkis","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_sbref0595","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Julien","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_bib0600","doi-asserted-by":"crossref","first-page":"12438","DOI":"10.1073\/pnas.1307382110","article-title":"Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer","volume":"110","author":"Mao","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2015.05.007_bib0605","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nsmb.2711","article-title":"Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy","volume":"20","author":"Bartesaghi","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.coi.2015.05.007_sbref0610","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion HIV-1 Env","volume":"514","author":"Pancera","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coi.2015.05.007_bib0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-Independent HIV-1 Env Trimers engineered as soluble native spike mimetics for vaccine design","author":"Sharma","year":"2015","journal-title":"Cell Reports"},{"key":"10.1016\/j.coi.2015.05.007_bib0620","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1016\/j.vaccine.2009.06.037","article-title":"Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1","volume":"27","author":"Kang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2015.05.007_bib0625","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virol.2014.03.015","article-title":"Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques","volume":"456-457","author":"Tong","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.coi.2015.05.007_bib0630","doi-asserted-by":"crossref","first-page":"e1004337","DOI":"10.1371\/journal.ppat.1004337","article-title":"HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunization","volume":"10","author":"Navis","year":"2014","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.coi.2015.05.007_bib0635","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_sbref0640","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1259206","article-title":"HIV antibodies Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies","volume":"346","author":"McGuire","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coi.2015.05.007_bib0645","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2015.05.007_bib0650","doi-asserted-by":"crossref","first-page":"13113","DOI":"10.1021\/ja405990z","article-title":"Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines","volume":"135","author":"Aussedat","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.coi.2015.05.007_bib0655","doi-asserted-by":"crossref","first-page":"18214","DOI":"10.1073\/pnas.1317855110","article-title":"Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors","volume":"110","author":"Alam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2015.05.007_bib0660","doi-asserted-by":"crossref","first-page":"e1002200","DOI":"10.1371\/journal.ppat.1002200","article-title":"Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies","volume":"7","author":"Ma","year":"2011","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.coi.2015.05.007_bib0665","doi-asserted-by":"crossref","first-page":"11725","DOI":"10.1128\/JVI.05680-11","article-title":"Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation","volume":"85","author":"Alam","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2015.05.007_bib0670","doi-asserted-by":"crossref","first-page":"e27824","DOI":"10.1371\/journal.pone.0027824","article-title":"Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41","volume":"6","author":"Dennison","year":"2011","journal-title":"PLoS One"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791515000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791515000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:30:14Z","timestamp":1760603414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791515000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":67,"alternative-id":["S0952791515000801"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2015.05.007","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725546301.793518516","asserted-by":"object"}]},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New approaches to HIV vaccine development","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2015.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}